China has approved 19 innovative medicines — including major treatments from Eli Lilly, Pfizer, and Johnson & Johnson — for its first commercial health insurance drug catalog, creating a new pathway for companies to sell advanced therapies at better prices.
The announcement was made Sunday in Guangzhou, marking a major shift in how China plans to support costly drugs that are too expensive for its state insurance program.
